EVRA (manufactured by LTS Lohmann Therapie-Systeme AG) is a transdermal patch containing 6 mg NGMN and 600 micrograms EE.
Each EVRA transdermal patch has a contact surface area of 20 cm2 and is designed to provide continuous delivery of NGMN and EE into the bloodstream over a seven-day duration of wear (see Pharmacology: Pharmacokinetics under Actions).
EVRA is a thin, matrix-type transdermal patch consisting of three layers: The backing layer is composed of a beige flexible film consisting of a low-density pigmented polyethylene outer layer and a polyester inner layer. It provides structural support and protects the middle adhesive layer from the environment.
The middle layer contains polyisobutylene/polybutene adhesive, crospovidone, non-woven polyester fabric and lauryl lactate as inactive components. The active components in this layer are the hormones, norelgestromin (NGMN) and ethinyl estradiol (EE).
The third layer is the release liner, which protects the adhesive layer during storage and is removed just prior to application. It is a transparent polyethylene terephthalate (PET) film with a polydimethylsiloxane coating on the side that is in contact with the middle adhesive layer.
Excipients/Inactive Ingredients: Backing layer: Low-density pigmented polyethylene outer layer, polyester inner layer.
Middle layer: Polyisobutylene/polybutene adhesive, crospovidone, non-woven polyester fabric and lauryl lactate.
Third layer: Transparent polyethylene terephthalate (PET) film with a polydimethylsiloxane coating.